Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
LEXINGTON, Mass., March 16, 2016 -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2015 on Wednesday, March 30, 2016, prior to the market open.
The Company will hold a conference call on Wednesday, March 30, 2016 at 8:30 a.m. ET to discuss the results. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers. The conference ID number for both is 13632696. A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com.
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year. In addition, a telephonic replay of the call will be available until April 13, 2016. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13632696.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has completed Phase IIa testing of NS2 in subjects with induced allergic conjunctivitis, and has initiated clinical testing of NS2 for the treatment of noninfectious anterior uveitis and Sjögren-Larsson Syndrome. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com
Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 ext. 205 [email protected] Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 [email protected]
